HK1008834A1 - Cytokine synthesis inhibitory factor and methods of using same - Google Patents

Cytokine synthesis inhibitory factor and methods of using same

Info

Publication number
HK1008834A1
HK1008834A1 HK98109520A HK98109520A HK1008834A1 HK 1008834 A1 HK1008834 A1 HK 1008834A1 HK 98109520 A HK98109520 A HK 98109520A HK 98109520 A HK98109520 A HK 98109520A HK 1008834 A1 HK1008834 A1 HK 1008834A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
synthesis inhibitory
cytokine synthesis
inhibitory factor
Prior art date
Application number
HK98109520A
Other languages
English (en)
Inventor
Timothy R Mosmann
Kevin W Moore
Martha Bond
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1008834A1 publication Critical patent/HK1008834A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK98109520A 1989-06-28 1998-07-29 Cytokine synthesis inhibitory factor and methods of using same HK1008834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20
PCT/US1990/003554 WO1991000349A1 (en) 1989-06-28 1990-06-28 Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same

Publications (1)

Publication Number Publication Date
HK1008834A1 true HK1008834A1 (en) 1999-05-21

Family

ID=27005854

Family Applications (3)

Application Number Title Priority Date Filing Date
HK98109520A HK1008834A1 (en) 1989-06-28 1998-07-29 Cytokine synthesis inhibitory factor and methods of using same
HK02101932.7A HK1040493B (zh) 1989-06-28 2002-03-13 哺乳動物細胞激動素合成抑制因子的製藥用途
HK02101934.5A HK1040531B (zh) 1989-06-28 2002-03-13 製備哺乳動物細胞激動素合成抑制因子的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK02101932.7A HK1040493B (zh) 1989-06-28 2002-03-13 哺乳動物細胞激動素合成抑制因子的製藥用途
HK02101934.5A HK1040531B (zh) 1989-06-28 2002-03-13 製備哺乳動物細胞激動素合成抑制因子的方法

Country Status (22)

Country Link
EP (2) EP0567450B1 (fi)
JP (1) JP2813063B2 (fi)
KR (1) KR0183035B1 (fi)
CN (3) CN1318589C (fi)
AT (1) ATE180833T1 (fi)
AU (1) AU635058B2 (fi)
CA (1) CA2062763C (fi)
CS (1) CS414591A3 (fi)
DE (1) DE69033143T2 (fi)
DK (1) DK0567450T3 (fi)
ES (1) ES2132068T3 (fi)
FI (1) FI107926B (fi)
GR (1) GR3030404T3 (fi)
HK (3) HK1008834A1 (fi)
HU (1) HU216310B (fi)
IL (1) IL94878A (fi)
NO (1) NO301718B1 (fi)
NZ (1) NZ234291A (fi)
PT (1) PT94514B (fi)
SG (1) SG52282A1 (fi)
TW (1) TW218383B (fi)
WO (1) WO1991000349A1 (fi)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
CZ282523B6 (cs) * 1991-01-16 1997-07-16 Schering Corporation Iterleukin - 10 pro léčení nádorů, farmaceutický prostředek jej obsahující, jeho použití a způsob výroby
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
IE68836B1 (en) * 1991-01-16 1996-07-10 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
EP0600970B1 (en) * 1991-08-06 1999-12-08 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
RU2120802C1 (ru) * 1992-08-20 1998-10-27 Шеринг Корпорейшн Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
WO1994006473A1 (en) * 1992-09-18 1994-03-31 Schering Corporation Restoration of immunocompetency to t helper cells in hiv infected patients
CA2145863A1 (en) * 1992-10-01 1994-04-28 Martha W. Bond Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
ZA945434B (en) * 1993-07-26 1995-01-23 Schering Corp Agonists and antagonists of human interleukin-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
PT769054E (pt) 1994-07-05 2000-11-30 Steeno Res Group A S Imunoreguladores
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN100389126C (zh) * 1995-12-13 2008-05-21 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
AU734807B2 (en) * 1996-04-17 2001-06-21 Patrick T. Prendergast Dhea combination therapy
EP0925072A2 (en) * 1996-09-06 1999-06-30 Schering Corporation Method for lowering cholesterol levels
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
WO2000073457A1 (en) * 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
WO2001074388A1 (en) 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP2582386A2 (en) 2010-06-16 2013-04-24 Allergan, Inc. Il-10 and methods of treating ocular and other diseases
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
PH31669A (en) * 1989-12-20 1999-01-18 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma.

Also Published As

Publication number Publication date
SG52282A1 (en) 1998-09-28
GR3030404T3 (en) 1999-09-30
HK1040531A1 (en) 2002-06-14
NO301718B1 (no) 1997-12-01
PT94514A (pt) 1991-04-18
DK0567450T3 (da) 1999-12-13
DE69033143T2 (de) 1999-10-21
EP0405980A1 (en) 1991-01-02
JPH04502560A (ja) 1992-05-14
PT94514B (pt) 1998-02-27
CN1318589C (zh) 2007-05-30
EP0567450A1 (en) 1993-11-03
NZ234291A (en) 1992-11-25
NO915115L (no) 1992-02-26
CN1198642C (zh) 2005-04-27
WO1991000349A1 (en) 1991-01-10
AU6077090A (en) 1991-01-17
CN1317343A (zh) 2001-10-17
IL94878A0 (en) 1991-04-15
IL94878A (en) 2003-01-12
DE69033143D1 (de) 1999-07-08
JP2813063B2 (ja) 1998-10-22
TW218383B (fi) 1994-01-01
HK1040493A1 (en) 2002-06-14
FI916126A0 (fi) 1991-12-27
HU216310B (hu) 1999-06-28
KR0183035B1 (ko) 1999-04-01
EP0567450B1 (en) 1999-06-02
CN1051393A (zh) 1991-05-15
HU906705D0 (en) 1992-03-30
CA2062763A1 (en) 1990-12-29
CN1317569A (zh) 2001-10-17
CS414591A3 (en) 1992-12-16
HUT61048A (en) 1992-11-30
HK1040493B (zh) 2005-12-16
NO915115D0 (no) 1991-12-27
KR920701437A (ko) 1992-08-11
ES2132068T3 (es) 1999-08-16
AU635058B2 (en) 1993-03-11
FI107926B (fi) 2001-10-31
HK1040531B (zh) 2008-01-11
ATE180833T1 (de) 1999-06-15
CA2062763C (en) 2010-01-05

Similar Documents

Publication Publication Date Title
TW218383B (fi)
CA2069428A1 (en) A mammalian cytokine, il-11
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
EP0361284A3 (en) T cell growth factor
NO922456D0 (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
EP0273778A3 (en) Synergistic behavior of csf-1 and g-csf
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
CA2050477A1 (en) T cell growth factor

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20100627